/GRAL
GRAL Stock - GRAIL, Inc.
Healthcare|Medical - Diagnostics & ResearchNASDAQ
$91.09+3.14%
+$2.77 (+3.14%) • Dec 19
50
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.85
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).53
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.0
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+1.5%upside
Target: $92.46
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for GRAL
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$90.18 – $92.00
TARGET (TP)$92.50
STOP LOSS$83.80
RISK/REWARD1:0.2
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta4.26
52W High$115.76
52W Low$16.56
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $125.59M | $93.11M | $55.55M | $14.61M | N/A |
| Gross Profit | $-78,022,000 | $-95,611,000 | $-116,447,000 | $-100,003,000 | N/A |
| Gross Margin | -62.1% | -102.7% | -209.6% | -684.4% | N/A |
| Operating Income | $-2,189,158,000 | $-1,515,382,000 | $-5,442,890,000 | $-1,265,342,000 | $-316,415,000 |
| Net Income | $-2,027,005,000 | $-1,465,685,000 | $-5,399,098,000 | $-1,247,775,000 | $-312,156,000 |
| Net Margin | -1613.9% | -1574.2% | -9719.3% | -8539.4% | N/A |
| EPS | $-63.54 | $-47.20 | $-173.87 | $-40.18 | $-2.52 |
Company Overview
GRAIL, Inc., a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. The company was incorporated in 2015 and is based in Menlo Park, California. GRAIL, Inc. operates as a former subsidiary of Illumina, Inc.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
2
40%
Hold / Neutral
3
60%
Sell / Underperform
0%
Analyst Consensus🔴 Bearish
2 Bullish3 Neutral/Bearish
Price Targets
$65
Average Target
↓ 29.2% Downside
Now
$16
Low
$65
Average
$110
High
Based on 4 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 2nd 2025 | Morgan Stanley | Resumed | Equal Weight | $110 |
| November 12th 2025 | Guggenheim | Upgrade | Buy | $100 |
| April 21st 2025 | Canaccord Genuity | Initiation | Buy | $32 |
| November 27th 2024 | Morgan Stanley | Initiation | Equal Weight | $16 |
| November 15th 2024 | Wolfe Research | Initiation | Peer Perform | - |
| October 17th 2024 | Guggenheim | Initiation | Neutral | - |
Earnings History & Surprises
GRALBeat Rate
80%
Last 5 quarters
Avg Surprise
+29.0%
EPS vs Estimate
Beats / Misses
4/1
Last 12 quarters
Latest EPS
$-2.46
Q4 2025
EPS Surprise History
Q4 23
No data
Q1 24
No data
Q3 24
No data
Q4 24
+38.7%
$-3.94vs$-6.43
Q1 25
+57.8%
$-1.86vs$-4.41
Q2 25
+23.1%
$-3.10vs$-4.03
Q3 25
-1.3%
$-3.18vs$-3.14
Q4 25
+26.8%
$-2.46vs$-3.36
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Feb 19, 2026 | $-3.33 | — | — | — |
Q4 2025 | Nov 12, 2025 | $-3.36 | $-2.46 | +26.8% | ✓ BEAT |
Q3 2025 | Aug 12, 2025 | $-3.14 | $-3.18 | -1.3% | ✗ MISS |
Q2 2025 | May 13, 2025 | $-4.03 | $-3.10 | +23.1% | ✓ BEAT |
Q1 2025 | Feb 20, 2025 | $-4.41 | $-1.86 | +57.8% | ✓ BEAT |
Q4 2024 | Nov 12, 2024 | $-6.43 | $-3.94 | +38.7% | ✓ BEAT |
Q3 2024 | Aug 13, 2024 | — | $-5.30 | — | — |
Q1 2024 | Mar 31, 2024 | — | $-7.05 | — | — |
Q4 2023 | Dec 31, 2023 | — | $-0.18 | — | — |
Q3 2023 | Sep 30, 2023 | — | $-28.71 | — | — |
Q2 2023 | Jun 29, 2023 | — | $-6.22 | — | — |
Q2 2023 | Apr 2, 2023 | — | $-6.24 | — | — |
Q3 2020 | Sep 29, 2020 | — | $-0.58 | — | — |
Q3 2019 | Sep 29, 2019 | — | $-0.49 | — | — |
Latest News
Morgan Stanley Maintains Equal-Weight on GRAIL, Raises Price Target to $110
📈 PositiveBenzinga•Dec 2, 2025, 05:39 PM
Deutsche Bank sets ‘holy grail' 2026 goal for the S&P 500
📈 PositiveDowjones•Nov 24, 2025, 02:29 PM•Also: , ,
Grail shares are trading higher after Canaccord Genuity maintained a Buy rating and raised its price target on the stock from $85 to $105.
📈 PositiveBenzinga•Nov 17, 2025, 04:57 PM•Also:
Canaccord Genuity Maintains Buy on GRAIL, Raises Price Target to $105
📈 PositiveBenzinga•Nov 17, 2025, 04:55 PM•Also:
Grail Launches $300 Million At-The-Market Equity Offering Through Morgan Stanley And TD Securities
➖ NeutralBenzinga•Nov 14, 2025, 11:24 AM
GRAL stock has given up its prior gain. GRAIL shares were trading higher after the company reported better-than-expected Q3 financial results.
➖ NeutralBenzinga•Nov 13, 2025, 07:16 PM
GRAIL shares are trading higher after the company reported better-than-expected Q3 financial results.
📈 PositiveBenzinga•Nov 13, 2025, 05:31 PM
GRAIL Q3 EPS $(2.46) Beats $(3.60) Estimate, Sales $36.194M Beat $34.700M Estimate
📈 PositiveBenzinga•Nov 12, 2025, 09:03 PM
Guggenheim Upgrades GRAIL to Buy, Announces $100 Price Target
📈 PositiveBenzinga•Nov 12, 2025, 01:46 PM
GRAIL shares are trading higher after Canaccord Genuity maintained a Buy rating and raised its price target from $75 to $85.
📈 PositiveBenzinga•Oct 24, 2025, 03:49 PM•Also: ,
Canaccord Genuity Maintains Buy on GRAIL, Raises Price Target to $85
📈 PositiveBenzinga•Oct 22, 2025, 01:53 PM•Also:
GRAIL shares are trading higher after the company announced a $325 million private placement financing.
📈 PositiveBenzinga•Oct 20, 2025, 12:46 PM
GRAIL announces equity offering of $325.0M
➖ NeutralSeeking Alpha•Oct 20, 2025, 10:48 AM
Grail Announces Private Placement Of 4.64M At $70.05 For Gross Proceeds Of Approximately $325M
➖ NeutralBenzinga•Oct 20, 2025, 10:38 AM
Grail's Galleri Test Shows Higher Accuracy In Detecting Hidden Cancers After 24-Month Follow-Up
📈 PositiveBenzinga•Oct 20, 2025, 10:15 AM
Grail And Oxford Study Finds Galleri Blood Test Caught Cancers Missed In Standard Checks
📈 PositiveBenzinga•Oct 20, 2025, 10:14 AM
Reported Firday, GRAIL's Galleri Test Detected More Than Seven Times The Number Of Cancers Compared To Routine USPSTF Screenings In PATHFINDER 2
📈 PositiveBenzinga•Oct 20, 2025, 08:30 AM
GRAIL Expects To Report That For Three Months Ended Sept 30, 2025 Total Revenue Of Between $35.7M To $36.7M; Expects To Report That For Three Months Ended Sept 30, 2025 Losses From Operations Of Between $123.9M To $126.9M; Expects To Report That It Had Cash, Cash Equivalents, Restricted Cash, Short-Term Marketable Securities As Of Sept 30 Of ~$547M
📉 NegativeBenzinga•Oct 16, 2025, 09:22 PM
GRAIL soars on $110M Samsung investment, strategic pact
📈 PositiveSeeking Alpha•Oct 16, 2025, 01:21 PM•Also:
GRAIL shares are trading higher after the company announced it signed a binding Letter of Intent for a strategic collaboration with Samsung C&T and Samsung Electronics to bring its Galleri multi-cancer early detection test to key Asian markets. Samsung C&T And Samsung Electronics also agreed to invest $110 million into the company.
📈 PositiveBenzinga•Oct 16, 2025, 12:38 PM•Also:
Frequently Asked Questions about GRAL
What is GRAL's current stock price?
GRAIL, Inc. (GRAL) is currently trading at $91.09 per share. The stock has moved +3.14% today.
What is the analyst price target for GRAL?
The average analyst price target for GRAL is $92.50, based on 1 analyst.
What sector is GRAIL, Inc. in?
GRAIL, Inc. operates in the Healthcare sector, specifically within the Medical - Diagnostics & Research industry. The company is traded on the NASDAQ exchange.
What is GRAL's market cap?
GRAIL, Inc. has a market capitalization of $3.19 billion, making it a mid-cap company.
Does GRAL pay dividends?
No, GRAIL, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAAPG
ASCENTAGE PHARMA GROUP INTERNATIONAL
$29.31
Mkt Cap: $2.7B
APGE
Apogee Therapeutics, Inc.
$78.54
Mkt Cap: $4.3B
CELC
Celcuity Inc.
$101.16
Mkt Cap: $4.7B
CNTA
Centessa Pharmaceuticals plc
$24.85
Mkt Cap: $3.3B
DYN
Dyne Therapeutics, Inc.
$19.85
Mkt Cap: $2.8B
IDYA
IDEAYA Biosciences, Inc.
$33.55
Mkt Cap: $2.9B
NVST
Envista Holdings Corp
$22.28
Mkt Cap: $3.7B
RARE
Ultragenyx Pharmaceutical Inc.
$33.50
Mkt Cap: $3.2B
SLNO
Soleno Therapeutics, Inc.
$47.85
Mkt Cap: $2.6B
XENE
Xenon Pharmaceuticals Inc.
$44.10
Mkt Cap: $3.4B
Explore stocks similar to GRAL for comparison